Evidence map›Paper›PMID 39478321›Full record

ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2026

Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections.

Julia C Dombrowski, Deborah Donnell, Cole Grabow, Stephanie E Cohen, Chase A Cannon, Clare E Brown, Susan P Buchbinder, Connie Celum, Anne F Luetkemeyer

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. DoxyPEP: Opportunities for Expansion.Journal of primary care & community health
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Julia C DombrowskiDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-1907-9428
Deborah DonnellVaccine and Infectious Disease Division, Fred Hutch Cancer Center, Seattle, Washington, USA.
Cole GrabowDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-2006-8654
Stephanie E CohenDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0002-1632-1074
Chase A CannonDepartment of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-2962-754X
Clare E BrownDepartment of Global Health, University of Washington, Seattle, Washington, USA.ORCID 0000-0003-3963-1339
Susan P BuchbinderDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0003-2404-0712
Connie CelumDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Anne F LuetkemeyerDepartment of Medicine, University of California, San Francisco, California, USA.ORCID 0000-0003-0911-1578

Funding

Evaluation of doxycycline post-exposure prophylaxis to reduce sexually transmitted infections in PrEP users and HIV-infected men who have sex with menR01AI143439 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CELUM, CONNIE L, LUETKEMEYER, ANNE FREY · 2019 to 2023
$8.3M
NIAID NIH HHS R01 AI143439NIH HHS R01 AI143439
6 · The paper itself

Abstract

Doxycycline postexposure prophylaxis (doxy-PEP) reduces the risk of bacterial sexually transmitted infections among men who have sex with men and transgender women. In the United States, doxy-PEP is in an early stage of integration into clinical practice, and national guidelines for its use were recently released. The goal of this manuscript is to provide practical guidance for clinicians who are considering or currently prescribing doxy-PEP. We address 5 clinical questions using post hoc analyses of data from the DoxyPEP randomized controlled trial and discuss the potential implications and limitations of each question with the goal of informing clinical practice and implementation of doxy-PEP programs. The questions address patient eligibility criteria for doxy-PEP, the expected benefit and associated doxy-PEP doses for the average patient, the initial number of doses prescribed, and laboratory monitoring of persons taking doxy-PEP.

Indexed as

Anti-Bacterial AgentsDoxycyclinePost-Exposure ProphylaxisSexually Transmitted Diseases, BacterialFemaleHumansMaleUnited StatesAnti-Bacterial AgentsDoxycyclinedelivery of healthcaredoxycycline prophylaxisHIVHIV preexposure prophylaxissexually transmitted infections

Identifiers

PMID39478321
PMCPMC13370436

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.